Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 3/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2629004 | 0.82 | HTR7 (0.41) | HTR7MAPT | |
| SCHEMBL12301543 | 0.79 | HTR7 (0.45) | HTR7CHRNB2CHRNA4MAPTHRH3 | |
| SCHEMBL22518694 | 0.79 | GABRP (0.38) | HTR7CHRNB2CHRNA4MAPT | |
| SCHEMBL30181381 | 0.78 | HTR7 (0.44) | HTR7CHRNB2CHRNA4MAPTTDO2 | |
| SCHEMBL14992817 | 0.78 | HTR7 (0.44) | HTR7CHRNB2CHRNA4MAPTHRH3 | |
| SCHEMBL608748 | 0.78 | HTR7 (0.44) | HTR7CHRNB2CHRNA4MAPTTDO2 | |
| SCHEMBL16631943 | 0.77 | GABRP (0.40) | MAPT | |
| SCHEMBL14992866 | 0.77 | PIK3CD (0.35) | HTR7 | |
| SCHEMBL1181640 | 0.76 | HTR7 (0.54) | HTR7CHRNB2CHRNA4TDO2 | |
| SCHEMBL22518736 | 0.74 | EPHX2 (0.38) | HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11071736-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION | 2021-07-27 | — | — | US | disclosed |
| US-10588909-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2020-03-17 | — | — | US | disclosed |
| EP-2785714-B1 | IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORP (TW) | 2018-11-21 | — | — | EP | disclosed |
| US-20180318310-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | DEVELOPMENT CENTER OF BIOTECHNOLOGY (TW) | 2018-11-08 | — | — | US | disclosed |
| US-20150250794-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORP (TW) | 2015-09-10 | — | — | US | disclosed |
| US-20150250794-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORP (TW) | 2015-09-10 | — | — | US | disclosed |
| US-20150250794-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORP (TW) | 2015-09-10 | — | — | US | disclosed |
| US-8999983-B2 | Modulators of Hec1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2015-04-07 | — | — | US | disclosed |
| US-8999983-B2 | Modulators of Hec1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2015-04-07 | — | — | US | disclosed |
| US-8999983-B2 | Modulators of Hec1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2015-04-07 | — | — | US | disclosed |
| EP-2785714-A1 | IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | Taivex Therapeutics Corporation (TW) | 2014-10-08 | — | — | EP | disclosed |
| US-20130190312-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORPORATION (TW) | 2013-07-25 | — | — | US | disclosed |
| US-20130190312-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORPORATION (TW) | 2013-07-25 | — | — | US | disclosed |
| US-20130190312-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORPORATION (TW) | 2013-07-25 | — | — | US | disclosed |
| WO-2013082324-A1 | IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORPORATION (TW) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013082324-A1 | IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORPORATION (TW) | 2013-06-06 | — | — | WO | disclosed |
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| WO-2008099000-A2 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180318310-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | WEE1, WEE2, NEK11 | HTR7 1448/4885CHRNB2 2242/4885CHRNA4 2842/4885 |
| US-20130190312-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | WEE1, WEE2, NEK11 | HTR7 1448/4885CHRNB2 2242/4885CHRNA4 2842/4885 |
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | PYGL, PYGM, G6PC1 | HTR7 3217/4885CHRNB2 3440/4885CHRNA4 2408/4885 |
| US-20150250794-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | WEE1, WEE2, NEK11 | HTR7 1448/4885CHRNB2 2242/4885CHRNA4 2842/4885 |
| US-10588909-B2 | Modulators of HEC1 activity and methods therefor | WEE1, WEE2, NEK11 | HTR7 1448/4885CHRNB2 2242/4885CHRNA4 2842/4885 |
| US-11071736-B2 | Modulators of HEC1 activity and methods therefor | WEE1, WEE2, NEK11 | HTR7 1448/4885CHRNB2 2242/4885CHRNA4 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.